Cell Penetrating Peptides and Uses Thereof, Entrada Therapeutics, EP3613426A1
Summary
Entrada Therapeutics, Inc. filed European patent application EP3613426A1 for cell penetrating peptides on April 15, 2026, covering therapeutic uses including treatments for cancer (A61P35/00), diabetes (A61P3/10), and kidney disease (A61P13/00). The application is classified under multiple IPC codes including C07K7/06, A61K38/00, A61K38/05, A61K38/12, A61K38/46, and A61K47/64, with inventors named as PEI, Dehua and QIAN, Ziqing. The application designates multiple European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
The EPO Patent Bulletin published application EP3613426A1 for Entrada Therapeutics, Inc., covering cell penetrating peptide compositions and their therapeutic uses. The application specifies multiple therapeutic indications including oncology (A61P35/00), metabolic disorders (A61P3/10), and renal conditions (A61P13/00), with inventors PEI, Dehua and QIAN, Ziqing listed. Designated contracting states span most major European jurisdictions. This is a publication of the patent application (Kind A1), not a granted patent, and remains subject to examination and potential opposition before any patent rights are conferred.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CELL PENETRATING PEPTIDES AND USES THEREOF
Publication EP3613426A1 Kind: A1 Apr 15, 2026
Applicants
Entrada Therapeutics, Inc.
Inventors
PEI, Dehua, QIAN, Ziqing
IPC Classifications
C07K 7/06 20060101AFI20260309BHEP C07K 7/00 20060101ALI20260309BHEP A61K 38/00 20060101ALI20260309BHEP A61K 38/05 20060101ALI20260309BHEP A61K 38/12 20060101ALI20260309BHEP A61K 38/46 20060101ALI20260309BHEP A61K 47/64 20170101ALI20260309BHEP A61P 35/00 20060101ALI20260309BHEP A61P 13/00 20060101ALI20260309BHEP A61P 3/10 20060101ALI20260309BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.